Silence Therapeutics PLC (SLN)
13.98
-1.30
(-8.54%)
USD |
NASDAQ |
Nov 14, 16:00
13.98
0.00 (0.00%)
After-Hours: 20:00
Silence Therapeutics Enterprise Value: 525.86M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 525.86M |
| November 12, 2024 | 569.39M |
| November 11, 2024 | 631.63M |
| November 08, 2024 | 630.69M |
| November 07, 2024 | 644.73M |
| November 06, 2024 | 652.69M |
| November 05, 2024 | 635.37M |
| November 04, 2024 | 645.20M |
| November 01, 2024 | 638.18M |
| October 31, 2024 | 620.40M |
| October 30, 2024 | 622.27M |
| October 29, 2024 | 653.15M |
| October 28, 2024 | 656.43M |
| October 25, 2024 | 656.90M |
| October 24, 2024 | 651.75M |
| October 23, 2024 | 654.09M |
| October 22, 2024 | 653.15M |
| October 21, 2024 | 651.75M |
| October 18, 2024 | 652.69M |
| October 17, 2024 | 676.55M |
| October 16, 2024 | 677.49M |
| October 15, 2024 | 666.73M |
| October 14, 2024 | 689.66M |
| October 11, 2024 | 730.37M |
| October 10, 2024 | 709.31M |
| Date | Value |
|---|---|
| October 09, 2024 | 713.99M |
| October 08, 2024 | 721.01M |
| October 07, 2024 | 681.70M |
| October 04, 2024 | 683.10M |
| October 03, 2024 | 712.59M |
| October 02, 2024 | 671.87M |
| October 01, 2024 | 663.92M |
| September 30, 2024 | 661.58M |
| September 27, 2024 | 664.85M |
| September 26, 2024 | 626.48M |
| September 25, 2024 | 656.43M |
| September 24, 2024 | 664.39M |
| September 23, 2024 | 653.15M |
| September 20, 2024 | 665.79M |
| September 19, 2024 | 667.66M |
| September 18, 2024 | 665.32M |
| September 17, 2024 | 663.92M |
| September 16, 2024 | 663.92M |
| September 13, 2024 | 685.44M |
| September 12, 2024 | 680.30M |
| September 11, 2024 | 679.36M |
| September 10, 2024 | 690.59M |
| September 09, 2024 | 697.14M |
| September 06, 2024 | 683.57M |
| September 05, 2024 | 692.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
88.18M
Minimum
Apr 24 2023
1.152B
Maximum
Mar 04 2024
496.32M
Average
536.73M
Median
Feb 08 2022
Enterprise Value Benchmarks
| NuCana PLC | -11.17M |
| TC BioPharm (Holdings) PLC | -0.7829M |
| Biodexa Pharmaceuticals PLC | -3.094M |
| Adaptimmune Therapeutics PLC | 6.629M |
| Verona Pharma PLC | 2.807B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.63M |
| Revenue (Quarterly) | 0.7545M |
| Total Expenses (Quarterly) | 23.87M |
| EPS Diluted (Quarterly) | -0.4201 |
| Gross Profit Margin (Quarterly) | -341.1% |
| Profit Margin (Quarterly) | -2.60K% |
| Earnings Yield | -8.73% |
| Normalized Earnings Yield | -8.732 |